- Home
- SGHT vs IMMP Comparison
SGHT vs IMMP Comparison
Compare SGHT & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGHT
- IMMP
- Stock Information
- Founded
- SGHT 2011
- IMMP 1987
- Country
- SGHT United States
- IMMP Australia
- Employees
- SGHT N/A
- IMMP N/A
- Industry
- SGHT Medical Specialities
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- SGHT Health Care
- IMMP Health Care
- Exchange
- SGHT Nasdaq
- IMMP Nasdaq
- Market Cap
- SGHT 304.4M
- IMMP 304.0M
- IPO Year
- SGHT 2021
- IMMP N/A
- Fundamental
- Price
- SGHT $2.89
- IMMP $1.91
- Analyst Decision
- SGHT Buy
- IMMP Buy
- Analyst Count
- SGHT 7
- IMMP 2
- Target Price
- SGHT $5.10
- IMMP $8.50
- AVG Volume (30 Days)
- SGHT 260.5K
- IMMP 95.6K
- Earning Date
- SGHT 03-06-2025
- IMMP 02-27-2025
- Dividend Yield
- SGHT N/A
- IMMP N/A
- EPS Growth
- SGHT N/A
- IMMP N/A
- EPS
- SGHT N/A
- IMMP N/A
- Revenue
- SGHT $79,543,000.00
- IMMP $2,563,302.00
- Revenue This Year
- SGHT $2.13
- IMMP N/A
- Revenue Next Year
- SGHT $7.99
- IMMP $47.79
- P/E Ratio
- SGHT N/A
- IMMP N/A
- Revenue Growth
- SGHT N/A
- IMMP 9.59
- 52 Week Low
- SGHT $2.68
- IMMP $1.66
- 52 Week High
- SGHT $8.45
- IMMP $3.34
- Technical
- Relative Strength Index (RSI)
- SGHT 26.68
- IMMP 40.99
- Support Level
- SGHT $2.68
- IMMP $2.00
- Resistance Level
- SGHT $3.34
- IMMP $2.05
- Average True Range (ATR)
- SGHT 0.16
- IMMP 0.09
- MACD
- SGHT -0.03
- IMMP -0.02
- Stochastic Oscillator
- SGHT 20.38
- IMMP 2.78
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.